MCID: PRS045
MIFTS: 47

Prostatic Hypertrophy

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 11 14 71
Benign Prostatic Hypertrophy 71
Prostatic Hyperplasia 71

Classifications:



External Ids:

Disease Ontology 11 DOID:11132
UMLS 71 C0005001 C1739363 C2937421

Summaries for Prostatic Hypertrophy

MalaCards based summary: Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to bladder neck obstruction and prostatic adenoma, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is LGALS8 (Galectin 8), and among its related pathways/superpathways are Coregulation of Androgen receptor activity and Regulation of Androgen receptor activity. The drugs Finasteride and Diclofenac have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and heart, and related phenotypes are renal/urinary system and muscle

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 565)
# Related Disease Score Top Affiliating Genes
1 bladder neck obstruction 31.4 PDE5A KLK3 ACE
2 prostatic adenoma 31.0 SHBG SERPINA3 KLK3 AR
3 urethral stricture 30.8 PDE5A KLK3 FOLH1 CRP ADRA1D
4 urinary tract obstruction 30.6 KLK3 CRP ALB ACE
5 prostatic hyperplasia, benign 30.6 SRD5A2 SERPINA3 PDE5A PCA3 KLK3 KLK2
6 impotence 30.5 SHBG PDE5A KLK3 AR ADRA1D ACE
7 prostatitis 30.5 PDE5A PCA3 KLK3 AR ADRA1A
8 suppression of tumorigenicity 12 30.3 SERPINA3 KLK3 FOLH1 AR
9 prostate disease 30.2 SERPINA3 PCA3 KLK3 KLK2 FOLH1 AR
10 pyelonephritis 30.1 CRP ALB ACE
11 sexual health disorder 30.0 SRD5A2 SHBG PDE5A AR
12 urethritis 30.0 KLK3 CRP ALB
13 inguinal hernia 29.9 SRD5A2 KLK3 INS CRP AR ALB
14 gynecomastia 29.9 SRD5A2 SHBG KLK3 ESR1 AR
15 coronary heart disease 1 29.9 INS CRP ACE
16 syphilis 29.9 CRP ALB ACE
17 prostate cancer 29.8 SRD5A2 SHBG SERPINA3 PCA3 KLK3 KLK2
18 urinary system disease 29.8 SERPINA3 KLK3 ALB ACE
19 chronic pyelonephritis 29.8 SERPINA3 CRP ALB ACE
20 acute myocardial infarction 29.8 INS CRP ALB ACE
21 diabetic neuropathy 29.8 INS ALB ACE
22 pulmonary embolism 29.7 PDE5A CRP ALB ACE
23 neurogenic bladder 29.7 PDE5A KLK3 INS CRP ALB ACE
24 varicocele 29.7 SHBG ESR1 AR ALB
25 sleep disorder 29.6 INS CRP ALB ACE
26 uremia 29.6 INS CRP ALB ACE
27 pyuria 29.6 KLK3 CRP ATP4A ATP12A ALB
28 chronic kidney disease 29.6 INS ESR1 CRP ALB ACE
29 hypogonadotropic hypogonadism 29.5 SRD5A2 SHBG INS ESR1 AR
30 pernicious anemia 29.5 INS ATP4A ATP12A
31 substance abuse 29.5 SERPINA3 INS CRP ALB ACE
32 cerebrovascular disease 29.5 SERPINA3 INS CRP ALB ACE
33 urinary tract infection 29.4 SERPINA3 KLK3 INS CRP ATP4A ATP12A
34 dysentery 29.1 SERPINA3 CRP ATP4A ATP12A ALB
35 lipid metabolism disorder 29.1 SHBG SERPINA3 PDE5A INS CRP ALB
36 type 2 diabetes mellitus 28.7 SHBG SERPINA3 PDE5A INS ESR1 CRP
37 deficiency anemia 28.6 SERPINA3 INS CRP ATP4A ATP12A ALB
38 adenoma 10.5
39 prostate adenoid cystic carcinoma 10.4 KLK3 AR
40 prostate leiomyoma 10.4 KLK3 AR
41 prostate calculus 10.4 KLK3 AR
42 prostatic cyst 10.4 KLK3 EPPIN
43 nodular prostate 10.4 KLK3 FOLH1
44 male reproductive organ benign neoplasm 10.3 SERPINA3 KLK3 AR
45 inhibited female orgasm 10.3 SHBG PDE5A
46 vasculogenic impotence 10.3 PDE5A ACE
47 prostatic acinar adenocarcinoma 10.3 KLK3 FOLH1 AR
48 prostate small cell carcinoma 10.3 KLK3 FOLH1 AR
49 prostate neuroendocrine neoplasm 10.3 KLK3 FOLH1 AR
50 castration-resistant prostate carcinoma 10.3 KLK3 FOLH1 AR

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show all 50)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Cancer
Bladder Disease Bladder Neck Obstruction
Chronic Kidney Disease Cystitis
Cystitis Cystica Epididymo-Orchitis
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Hydronephrosis
Infected Hydrocele Interstitial Cystitis
Kidney Disease Left Bundle Branch Hemiblock
Lipoma of Spermatic Cord Low Compliance Bladder
Nephrolithiasis, X-Linked Recessive, with Renal Failure Neurogenic Bladder
Parkinson Disease, Late-Onset Pelvic Varices
Penile Disease Peyronie's Disease
Pinta Disease Pneumoconiosis
Postinflammatory Pulmonary Fibrosis Prostate Calculus
Prostate Cancer Prostate Carcinoma in Situ
Prostate Disease Prostatitis
Prostatocystitis Renal Pelvis Carcinoma
Right Bundle Branch Block Silicosis
Spermatocele Ureter, Cancer of
Ureterolithiasis Urethral Benign Neoplasm
Urethral Calculus Urethral Stricture
Urethritis Urinary Tract Obstruction
Varicocele Vesicoureteral Reflux 1

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.86 ACE ADRA1A ALB AR ATP12A EPPIN
2 muscle MP:0005369 9.76 ADRA1A ADRA1D ALB AR ESR1 INS
3 cardiovascular system MP:0005385 9.73 ACE ADRA1A ADRA1D ALB AR CRP
4 immune system MP:0005387 9.4 ACE ALB AR ATP4A CRP EPPIN

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Finasteride Approved Phase 4 98319-26-7 57363
2
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
3
Methyltestosterone Approved Phase 4 58-18-4 6010
4
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
5
Testosterone enanthate Approved Phase 4 315-37-7 9416
6
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
7
Saw palmetto Approved, Experimental, Investigational Phase 4
8
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
9
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Carbamide peroxide Approved Phase 4 124-43-6
12
Methoxyflurane Approved, Investigational, Vet_approved, Withdrawn Phase 4 76-38-0 4116
13
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
14
Dihydrotachysterol Approved Phase 4 67-96-9 5311071
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
17
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
18
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
19
Silodosin Approved Phase 4 160970-54-7 9891967 5312125
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
22
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
23
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
24
Mirabegron Approved Phase 4 223673-61-8 18319735 9865528
25
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
26
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
27
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
28
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
29
Sulfamethoxazole Approved Phase 4 723-46-6 5329
30
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
34
Stanolone Illicit, Investigational Phase 4 521-18-6 10635
35
Naftopidil Investigational Phase 4 57149-07-2 4418
36 5-alpha Reductase Inhibitors Phase 4
37 Androgens Phase 4
38 Anesthetics Phase 4
39 Cholinergic Agents Phase 4
40 Pharmaceutical Solutions Phase 4
41 Mitogens Phase 4
42 Testosterone 17 beta-cypionate Phase 4
43 Saw palmetto extract Phase 4
44 Citrate Phase 4
45
bilirubin Phase 4 635-65-4 5280352
46 N-Methylaspartate Phase 4
47 Calcium, Dietary Phase 4
48 calcium channel blockers Phase 4
49 Anesthetics, Inhalation Phase 4
50 Anesthetics, General Phase 4

Interventional clinical trials:

(show top 50) (show all 579)
# Name Status NCT ID Phase Drugs
1 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
2 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
3 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
4 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
5 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
6 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
7 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
8 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Unknown status NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
9 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
10 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
11 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
12 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
13 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
14 Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study Completed NCT01260129 Phase 4 Silodosin
15 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
16 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
17 Benign Prostatic Hyperplasia and Ischemic Heart DIsease Completed NCT03856242 Phase 4 Tamsulosin Oral Capsule
18 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
19 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
20 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
21 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
22 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
23 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
24 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
25 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
26 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
27 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
28 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
29 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
30 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
31 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Completed NCT02757768 Phase 4 Mirabegron;Placebo;Tamsulosin Hydrochloride
32 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
33 A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
34 A Pilot Study to Assess Efficacy and Safety of Methoxyflurane for Pain Control During Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH) Completed NCT04029012 Phase 4 Methoxyflurane
35 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
36 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
37 The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
38 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
39 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
40 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
41 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
42 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
43 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
44 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
45 An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms Completed NCT02715024 Phase 4 Tamsulosin;Solifenacin
46 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
47 Implementation of a Screening Tool for Subjects With Benign Prostatic Enlargement/Obstruction to Identify Men >=50 Years Presenting in General Practice With Other Co-morbidities Who Should be Assessed for BPH Completed NCT02757963 Phase 4
48 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction: A 24-Week Open-Label, Single-Arm Pilot Study Completed NCT00827814 Phase 4 Dutasteride
49 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
50 Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil. Completed NCT02252367 Phase 4 Tadalafil

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

Organs/tissues related to Prostatic Hypertrophy:

MalaCards : Prostate, Kidney, Heart, Endothelial, Smooth Muscle, Bone, Spinal Cord

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 2656)
# Title Authors PMID Year
1
[Urinary incontinence after endoscopic enucleation of the prostate with the Holmium laser: Evolutionary aspects and associated predictive factors]. 62
36424230 2022
2
[Complications in urological surgery: Prostate surgery]. 62
36410867 2022
3
Clinical Characteristics of Patients with Staphylococcus aureus Bile Infection. 62
36309859 2022
4
Ejaculation Sparing Thulium Laser Enucleation of the Prostate: An Observational Prospective Study. 62
36362593 2022
5
Correlation between prostate volume measured by ultrasound and symptoms severity score in patients with benign prostatic hypertrophy in Southeastern Nigeria. 62
35975376 2022
6
The feasibility of endourological surgery in low-resource settings. 62
35524768 2022
7
Acromegaly and male sexual health. 62
35364803 2022
8
Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study. 62
35888055 2022
9
Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response. 62
35812583 2022
10
Potential of pre-interventional magnetic resonance angiography for optimization of workflow and clinical outcome of prostatic arterial embolization. 62
35279621 2022
11
Safety of not withholding clopidogrel therapy during the immediate several days pre- and post-trans-urethral resection of prostate (TURP): a retrospective cohort study. 62
35195853 2022
12
Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis. 62
35026706 2022
13
Ex Vivo Comparison of Efficiency, Safety, and Surgeon Satisfaction in Four Commercial Morcellators. 62
34779660 2022
14
Robotic Urethral Reconstruction Outcomes in Men With Posterior Urethral Stenosis. 62
34968569 2022
15
Changes in Anesthesia Can Reduce Periprocedural Urinary Retention After EVAR. 62
34687889 2022
16
Impact of the COVID-19 Pandemic on Primary Health Care Disease Incidence Rates: 2017 to 2020. 62
34561213 2022
17
Understanding the needs of low-income countries: how urologists can help. 62
34738315 2022
18
Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma. 62
35049707 2022
19
Review of the Economics of Surgical Treatment Options for Benign Prostatic Hyperplasia. 62
35156176 2022
20
Concurrent laparoscopic totally extraperitoneal inguinal hernia repair and transurethral resection of prostate: Breaking with convention - A retrospective study. 62
35017395 2022
21
SERS Liquid Biopsy Profiling of Serum for the Diagnosis of Kidney Cancer. 62
35203443 2022
22
Ureteric orifice obstruction by catheter balloon Post-TURP: A rare cause of obstructive uropathy. 62
34849349 2022
23
Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine-n-butylbromide (Buscopan) During Gastrointestinal Endoscopy. 62
34877465 2021
24
[Learning of self-catheterization: For whom? Why? How?] 62
34456139 2021
25
Contemporary practice patterns of transurethral therapies for benign prostate hypertrophy: results of a worldwide survey. 62
34143283 2021
26
Diacerein ameliorates testosterone-induced benign prostatic hyperplasia in rats: Effect on oxidative stress, inflammation and apoptosis. 62
34450401 2021
27
Prostate Artery Embolization-Review of Indications, Patient Selection, Techniques and Results. 62
34768659 2021
28
The use of tamsulosin to prevent postoperative urinary retention in laparoscopic inguinal hernia repair: a randomized double-blind placebo-controlled study. 62
33025252 2021
29
Association of bacterial isolates and antimicrobial susceptibility between prostatic fluid and urine samples in canine prostatitis with concurrent cystitis. 62
34399384 2021
30
Invited Commentary: Prostatic Artery Embolization for Benign Prostatic Hypertrophy-Are We Ready for Prime Time? 62
34415809 2021
31
In-silico and in-vivo evaluation of sesamol and its derivatives for benign prostatic hypertrophy. 62
34466348 2021
32
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans. 62
33942370 2021
33
Increased SPC24 in prostatic diseases and diagnostic value of SPC24 and its interacting partners in prostate cancer. 62
34306192 2021
34
Perioperative Blood Loss after Preoperative Prostatic Artery Embolization in Patients Undergoing Simple Prostatectomy: A Propensity Score‒Matched Study. 62
34062272 2021
35
Parkinson disease risks: correctly identifying environmental factors for a chronic disease. 62
34060482 2021
36
Inhibitory Activities of Dimeric Ellagitannins Isolated from Cornus alba on Benign Prostatic Hypertrophy. 62
34204056 2021
37
Concurrent laparoscopic totally extraperitoneal inguinal hernia repair and transurethral resection of prostate: Breaking with convention - A retrospective study. 62
34045416 2021
38
Management of prostate cancer after holmium laser enucleation of the prostate. 62
33221258 2021
39
Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS. 62
33611089 2021
40
The clinical applications of five-alpha reductase inhibitors. 62
33872554 2021
41
A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases. 62
33277796 2021
42
Lunar cycle, seasonal variation, and prevalence of emergency urological presentations: correlation or coincidence?-A preliminary report. 62
34084121 2021
43
Evaluation of static and dynamic Pupillometry changes in men using Silodosin for benign prostatic hypertrophy. 62
33678164 2021
44
Unexpected case of large ureteric calculus being passed following prostatic artery embolisation. 62
33384937 2021
45
Using CT-guided stereotactic prostate radiation therapy (CT-SPRT) to assess sustained murine prostate ablation. 62
33753857 2021
46
GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition. 62
33539321 2021
47
The role of prostate-specific antigen in light of new scientific evidence: An update in 2020. 62
33408046 2021
48
The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study. 62
34247169 2021
49
The protective effect of Sophora japonica on prostatic hypertrophy and inflammation in rat. 62
32504221 2020
50
Prostatic artery embolization using three-dimensional cone-beam computed tomography. 62
32532575 2020

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.12 KLK3 KLK2 AR
2 10.82 KLK3 KLK2 AR
3 10.49 KLK3 INS ESR1 AR

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 male gonad development GO:0008584 9.86 SRD5A2 ESR1 AR ACE
2 acute-phase response GO:0006953 9.85 SERPINA3 INS CRP
3 cell-cell signaling GO:0007267 9.85 ADRA1A ADRA1D AR INS SRD5A2
4 neuron-glial cell signaling GO:0150099 9.71 ADRA1D ADRA1A
5 positive regulation of heart rate by epinephrine-norepinephrine GO:0001996 9.62 ADRA1D ADRA1A
6 positive regulation of vasoconstriction GO:0045907 9.43 ADRA1D ADRA1A ACE
7 regulation of systemic arterial blood pressure GO:0003073 9.1 KLK3 KLK2 AR

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 9.63 SHBG ESR1 AR
2 androgen binding GO:0005497 9.62 SHBG AR
3 adrenergic receptor activity GO:0004935 9.37 ADRA1D ADRA1A
4 P-type potassium transmembrane transporter activity GO:0008556 9.26 ATP4A ATP12A
5 P-type potassium:proton transporter activity GO:0008900 9.26 ATP4A ATP12A
6 alpha1-adrenergic receptor activity GO:0004937 8.92 ADRA1D ADRA1A

Sources for Prostatic Hypertrophy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....